# Evaluation of Clinical Equivalence Between Two Linaclotide Products in the Treatment of Chronic Idiopathic Constipation

> **NCT04804267** · PHASE3 · UNKNOWN · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 750 (estimated)

## Conditions studied

- Chronic Idiopathic Constipation

## Interventions

- **DRUG:** Linaclotide
- **DRUG:** LINZESS®
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04804267
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-05
- **Primary completion:** 2022-08-31
- **Final completion:** 2022-08-31
- **Target enrollment:** 750 (ESTIMATED)
- **Last updated:** 2021-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04804267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04804267, "Evaluation of Clinical Equivalence Between Two Linaclotide Products in the Treatment of Chronic Idiopathic Constipation". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04804267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*